Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer

被引：84

作者：

Song, Haa-Na ^{[1
,2
]}

Jung, Ki Sun ^{[1
]}

Yoo, Kwai Han ^{[1
]}

Cho, Jinhyun ^{[1
]}

Lee, Ji Yun ^{[1
]}

Lim, Sung Hee ^{[1
]}

Kim, Hae Su ^{[1
]}

Sun, Jong-Mu ^{[1
]}

Lee, Se-Hoon ^{[1
]}

Ahn, Jin Seok ^{[1
]}

Park, Keunchil ^{[1
]}

Choi, Yoon-La ^{[3
]}

Park, Woongyang ^{[4
,5
]}

Ahn, Myung-Ju ^{[1
]}

机构：

[1] Sungkyunkwan Univ, Div Hematol & Oncol, Samsung Med Ctr, Dept Med,Sch Med, Seoul, South Korea

[2] Gyeongsang Natl Univ, Dept Internal Med, Sch Med, Jinju, South Korea

[3] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Pathol, Seoul, South Korea

[4] Samsung Genome Inst, Seoul, South Korea

[5] Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 04期

关键词：

EGFR; T790M mutation; HM61713; C797S mutation;

D O I：

10.1016/j.jtho.2015.12.093

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

T790M mutation is most common resistant mechanism to epidermal growth factor receptor gene (EGFR) tyrosin kinase inhibitor (TKI). Several third-generation EGFR-mutant selective TKI, such as AZD9291 (AstraZeneca), Rociletinib (Clovis), or HM61713 (Hanmi) have been developed. Acquired resistant C797S mutation was known to be one of the resistance mechanisms of AZD9291, which has not been reported for HM61713 yet. This is the first case report of C797S mutation as resistance mechanism of HM61713. (C) 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

引用

页码：E45 / E47

页数：5

共 50 条

[1] EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Shuhang Wang
Stella T. Tsui
Christina Liu
Yongping Song
Delong Liu
Journal of Hematology & Oncology, 9
[2] EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Wang, Shuhang
Tsui, Stella T.
Liu, Christina
Song, Yongping
Liu, Delong
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
[3] Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
Yu, Helena A.
Tian, Shaozhou K.
Drilon, Alexander E.
Borsu, Laetitia
Riely, Gregory J.
Arcila, Maria E.
Ladanyi, Marc
JAMA ONCOLOGY, 2015, 1 (07) : 981 - 983
[4] EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Park, Sehhoon
Ku, Bo Mi
Jung, Hyun Ae
Sun, Jong-Mu
Ahn, Jin Seok
Lee, Se-Hoon
Park, Keunchil
Ahn, Myung-Ju
CANCER RESEARCH AND TREATMENT, 2020, 52 (04): : 1288 - 1290
[5] Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Thress, Kenneth S.
Paweletz, Cloud P.
Felip, Enriqueta
Cho, Byoung Chul
Stetsonl, Daniel
Dougherty, Brian
Lai, Zhongwu
Markovets, Aleksandra
Vivancos, Ana
Kuang, Yanan
Ercan, Dalia
Matthews, Sarah E.
Cantarini, Mireille
Barrett, J. Carl
Jaenne, Pasi A.
Oxnard, Geoffrey R.
NATURE MEDICINE, 2015, 21 (06) : 560 - 562
[6] Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Kenneth S Thress
Cloud P Paweletz
Enriqueta Felip
Byoung Chul Cho
Daniel Stetson
Brian Dougherty
Zhongwu Lai
Aleksandra Markovets
Ana Vivancos
Yanan Kuang
Dalia Ercan
Sarah E Matthews
Mireille Cantarini
J Carl Barrett
Pasi A Jänne
Geoffrey R Oxnard
Nature Medicine, 2015, 21 : 560 - 562
[7] C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?
Grabe, Tobias
Lategahn, Jonas
Rauh, Daniel
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (08): : 779 - 782
[8] Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Shuhang Wang
Shundong Cang
Delong Liu
Journal of Hematology & Oncology, 9
[9] Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Wang, Shuhang
Cang, Shundong
Liu, Delong
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
[10] The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge
Zhang, Yi-Chen
Zhou, Qing
Chen, Zhi-Hong
Zhang, Ming-Feng
Yang, Jin-Ji
Tu, Hai-Yan
Zhang, Xu-Chao
Xu, Chong-Rui
Yan, Hong-Hong
Peng, Xiao-Xiao
Bai, Xiao-Yan
Chuai, Shao-Kun
Ye, Jun-Yi
Wu, Yi-Long
SCIENCE BULLETIN, 2019, 64 (08) : 499 - 503

← 1 2 3 4 5 →